Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 10.1 to 8.2.
Financials
Financial year 2025
Bio-Homeopharma from Antwerpen, company number BE0452900522, closed financial year 2025 with a result of € 15,848 after tax. For that financial year Bio-Homeopharma recorded a gross margin of € 494,439 and equity of € 554,721. Compared with financial year 2024, the result moved from € -75,573 to € 15,848. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 554,721
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 15,848
▲ still € 75,573 loss in 2024
Profit after tax over the fiscal year.
€ 476,780
▼ 4% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 180,402.
People and assets in 2025
8.2
▼ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 450,941
▼ 14% vs 2024
€ 55,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,555
▼ 8% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 202,289
▼ 16% vs 2024
€ 41,186 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 159,830
▼ 1% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 53,147
▼ 7% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 537,301 | € 621,783 | € 504,766 | € 494,439 | ▼ 2% |
| Profit after taxes | € -23,157 | € 41,491 | € -75,573 | € 15,848 | ▲ € 91,421 |
| Equity | € 592,955 | € 614,446 | € 538,874 | € 554,721 | ▲ 3% |
| Total debts | € 648,532 | € 626,426 | € 596,445 | € 560,026 | ▼ 6% |
| Cash | € 416,205 | € 528,037 | € 497,291 | € 476,780 | ▼ 4% |
| Land & buildings | € 41,091 | € 0 | - | - | |
| Retained profit | € 218,636 | € 240,127 | € 164,554 | € 180,402 | ▲ 10% |
| Dividend | € 0 | € 20,000 | € 0 | € 0 | |
| Bank debt | € 316,873 | € 280,118 | € 241,941 | € 202,289 | ▼ 16% |
| Balance sheet total | € 1,241,488 | € 1,240,872 | € 1,135,319 | € 1,114,748 | ▼ 2% |
| Employees (FTE) | 11 | 10.1 | 9.2 | 8.2 | ▼ 1 |
Key figures of Bio-Homeopharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Bio-Homeopharma?
What happened at Bio-Homeopharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Nathalie Monstrey stepped down as director. NBB
- Godelieve Willemse stepped down as director. NBB
- PHARMALUX BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 15,848. Source: NBB ↗
- Nathalie Monstrey became a director. NBB
- Godelieve Willemse became a director. NBB
- PHARMALUX BV became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 23,157 loss in 2022 to € 15,848 profit in 2025.
Paid € 11,131 in corporate taxes since 2022.
Best year ever: 2023, with € 41,491 profit.
On average € 60,300 of value added per employee in 2025.
Management
The stake of PHARMALUX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Bio-HomeopharmaThe shares are held by PHARMALUX (99.3%).
Directors
According to the 2025 annual accounts
since 2023 · until 2029
since 2023 · until 2029
since 2023 · until 2029
Shareholders
99.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Luitenant Lippenslaan 1
2140 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.900.522
- VAT number
- BE 0452.900.522
- Registered office
- Luitenant Lippenslaan 1, 2140 Antwerpen
- Names & denominations
- Bio-Homeopharma · ZWITSERSE APOTEEK
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 31 May 1994
- Peppol
- Active · Active since 27 Mar 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers